newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase